Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 08:00 ET | Source: Kalaris Therapeutics, Inc.

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat...
April 04, 2025 08:00 ET | Source: Kalaris Therapeutics, Inc.

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

PALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and...
March 18, 2025 16:21 ET | Source: Kalaris Therapeutics, Inc.

Kalaris Announces Closing of Merger with AlloVir

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative...
March 12, 2025 16:01 ET | Source: AlloVir, Inc.

Kalaris and AlloVir Announce Stockholder Approval of Merger

PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and...
November 08, 2024 06:00 ET | Source: AlloVir, Inc.

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients...